Answers are grounded in this paper and cite their sources.
Progression from sepsis to septic shock remains a major determinant of adverse outcome despite timely antimicrobial therapy, source control, and organ support. IgM-enriched intravenous immunoglobulin (IVIG) has potential immunomodulatory and pathogen-neutralizing effects, but prior studies have been limited by biological heterogeneity and non-comparable control groups. We evaluated whether early adjunctive IgM-enriched IVIG was associated with a lower risk of progression from sepsis to septic shock, with the primary comparison restricted to patients with predefined early immune dysfunction. We performed a multicenter retrospective cohort study of adults admitted to participating tertiary intensive care units between June 2021 and June 2023 with Sepsis-3-defined sepsis but without septic shock at index ICU admission. Patients presenting with septic shock were excluded from the progression cohort ( n = 148). Twenty-eight patients who initiated IVIG but died before completing the 3-day regimen were excluded from the treatment-completer cohort; 18 baseline-eligible patients were retained in the initiation-based comparison. Sepsis diagnosis was systematically reassessed at 72 h using the complete clinical course, microbiological/culture data, evidence of infection, and SOFA-based organ dysfunction. Immune dysfunction was defined using laboratory values obtained within 4 h of ICU admission as an absolute lymphocyte count < 0.8 × 10^9/L and/or serum IgM < 0.6 g/L. The primary analysis compared immune phenotype-positive patients who received early IgM-enriched IVIG ( n = 147) with immune phenotype-positive patients who did not receive IVIG because the treatment cost was not covered by the applicable insurance/reimbursement system ( n = 43). Immune phenotype-negative patients receiving standard care ( n = 196) were retained as a descriptive reference group. The primary outcome was progression to Sepsis-3 septic shock within 28 days. A parsimonious multivariable logistic regression was the primary adjusted analysis; inverse probability of treatment weighting (IPTW) was used only as a sensitivity analysis. The final analytic cohort included 386 patients. In the eligibility-restricted initiation-based sensitivity analysis, progression to septic shock occurred in 51/165 (30.9%) IVIG initiators versus 13/43 (30.2%) untreated immune phenotype-positive patients (RR 1.02, 95% CI 0.62–1.70; Fisher exact P = 1.000). In the original treatment-completer comparison, shock occurred in 33/147 (22.4%) versus 13/43 (30.2%) (RR 0.74, 95% CI 0.43–1.28; Fisher exact P = 0.315). The prespecified adjusted OR was 0.63 (95% CI 0.29–1.38; P = 0.245). Complete-case IPTW yielded an OR of 0.65 (95% CI 0.30–1.41; robust P = 0.279). Neither comparison supports a causal inference or a demonstrated benefit. The eligibility-restricted initiation-based comparison showed similar septic shock incidence among IVIG initiators and untreated phenotype-positive patients, whereas the original treatment-completer comparison showed a numerically lower, non-significant incidence. Both comparisons are vulnerable to survival-related selection and time-zero misalignment and do not establish treatment efficacy.
No takes yet. Share an insight, caveat, or question.
Aydoğan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: